<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03767348</url>
  </required_header>
  <id_info>
    <org_study_id>RPL-001-16</org_study_id>
    <nct_id>NCT03767348</nct_id>
  </id_info>
  <brief_title>Study of RP1 Monotherapy and RP1 in Combination With Nivolumab</brief_title>
  <official_title>An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination With PD1 Blockade in Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Replimune Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Replimune Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1
      alone and in combination with nivolumab in adult subjects with advanced and/or refractory
      solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose
      (RP2D), as well as to evaluate preliminary efficacy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RP1 is a genetically modified herpes simplex type 1 virus that is designed to directly
      destroy tumors and to generate an anti-tumor immune response. This is a Phase 1/2, open
      label, multicenter, dose escalation and expansion, first-in-human (FIH) clinical study to
      evaluate the safety and tolerability, biodistribution, shedding, and preliminary efficacy of
      RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory
      solid tumors. The study will include a dose escalation phase for single agent RP1, an
      expansion phase with a combination of RP1 and nivolumab and a Phase 2 portion in specified
      tumor types for the combination therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of adverse events (AEs)</measure>
    <time_frame>26 months</time_frame>
    <description>Percentage of subjects with adverse events (AEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of serious adverse events (SAEs)</measure>
    <time_frame>26 months</time_frame>
    <description>Percentage of subjects with serious adverse events (SAEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of dose limiting toxicities (DLTs)</measure>
    <time_frame>26 months</time_frame>
    <description>Percentage of subjects with dose limiting toxicities (DLTs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of overall response rate (ORR)</measure>
    <time_frame>26 months</time_frame>
    <description>Percentage of overall response rate (ORR) for all participants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of RP1</measure>
    <time_frame>20 weeks</time_frame>
    <description>Assess the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of RP1 based on the safety and response data collected during Phase 1 Escalation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of biologic activity</measure>
    <time_frame>20 weeks</time_frame>
    <description>Percentage of subjects with biological activity determined by tumor biopsies and biomarker data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage subjects with detectable RP1</measure>
    <time_frame>20 weeks</time_frame>
    <description>Data gathered from blood, urine, swabs of injection site, dressings, and oral mucosa to determine the shedding and biodistribution of RP1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of complete response (CR)</measure>
    <time_frame>26 months</time_frame>
    <description>Percentage of subjects with a complete response (CR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median duration of response</measure>
    <time_frame>26 months</time_frame>
    <description>Median duration of response of subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median progression-free survival</measure>
    <time_frame>26 months</time_frame>
    <description>Median duration of progression-free survival of subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median overall survival</measure>
    <time_frame>26 months</time_frame>
    <description>Median overall survival rate of subjects</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">281</enrollment>
  <condition>Cancer</condition>
  <condition>Melanoma (Skin)</condition>
  <condition>Melanoma, Uveal</condition>
  <condition>Melanoma, Ocular</condition>
  <condition>Bladder Cancer</condition>
  <condition>Mismatch Repair Deficiency</condition>
  <condition>Microsatellite Instability</condition>
  <condition>Non-melanoma Skin Cancer</condition>
  <arm_group>
    <arm_group_label>Dose escalation of RP1 by intratumoral (IT) injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation of RP1 alone in 3 cohorts with IT injections in superficial tumors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose escalation of RP1 by IT injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation of RP1 alone in 3 cohorts with intratumoral injections in deep/visceral tumors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose expansion of RP1 and nivolumab intravenously (IV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doses of RP1 (IT) in superficial tumors with nivolumab (IV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose expansion of RP1 and nivolumab (IV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doses of RP1 (IT) in deep/visceral tumors with nivolumab (IV)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RP1 (IT) and nivolumab (IV) in melanoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with melanoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RP1 (IT) and nivolumab (IV) in bladder cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with bladder cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RP1 (IT) and nivolumab (IV) in MSI-H/dMMR solid tumors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with MSI-H or dMMR solid tumors</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RP1 (IT) and nivolumab (IV) in NMSC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with NMSC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RP1(IT) and nivo(IV) in anti-PD1 Refractory Cutaneous Melanoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Doses of RP1 (IT) in superficial or deep tumors with nivolumab (IV) in subjects with cutaneous melanoma who have been previously treated with anti-PD1 therapy for at least 12 weeks and have confirmed disease progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RP1</intervention_name>
    <description>Genetically modified herpes simplex type 1 virus for tumor lysis and immune stimulation</description>
    <arm_group_label>Dose escalation of RP1 by IT injection</arm_group_label>
    <arm_group_label>Dose escalation of RP1 by intratumoral (IT) injection</arm_group_label>
    <arm_group_label>Dose expansion of RP1 and nivolumab (IV)</arm_group_label>
    <arm_group_label>Dose expansion of RP1 and nivolumab intravenously (IV)</arm_group_label>
    <arm_group_label>RP1 (IT) and nivolumab (IV) in MSI-H/dMMR solid tumors</arm_group_label>
    <arm_group_label>RP1 (IT) and nivolumab (IV) in NMSC</arm_group_label>
    <arm_group_label>RP1 (IT) and nivolumab (IV) in bladder cancer</arm_group_label>
    <arm_group_label>RP1 (IT) and nivolumab (IV) in melanoma</arm_group_label>
    <arm_group_label>RP1(IT) and nivo(IV) in anti-PD1 Refractory Cutaneous Melanoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>nivolumab</intervention_name>
    <description>anti-PD-1 monoclonal antibody</description>
    <arm_group_label>Dose expansion of RP1 and nivolumab (IV)</arm_group_label>
    <arm_group_label>Dose expansion of RP1 and nivolumab intravenously (IV)</arm_group_label>
    <arm_group_label>RP1 (IT) and nivolumab (IV) in MSI-H/dMMR solid tumors</arm_group_label>
    <arm_group_label>RP1 (IT) and nivolumab (IV) in NMSC</arm_group_label>
    <arm_group_label>RP1 (IT) and nivolumab (IV) in bladder cancer</arm_group_label>
    <arm_group_label>RP1 (IT) and nivolumab (IV) in melanoma</arm_group_label>
    <arm_group_label>RP1(IT) and nivo(IV) in anti-PD1 Refractory Cutaneous Melanoma</arm_group_label>
    <other_name>Opdivo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be willing and able to participate and comply with all trial requirements and
             able to provide signed and dated informed consent prior to initiation of any trial
             procedures

          -  Male or Female ≥ 18 years of age

          -  Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1.

          -  At least one measurable and injectable lesion

          -  Have laboratory values (obtained ≤ 28 days prior to first infusion day) in accordance
             with the study protocol

          -  Women of child-bearing potential (WOCBP) must have a negative urine pregnancy test at
             screening and a negative urine pregnancy test prior to administration of each dose of
             RP1 or nivolumab

          -  WOCBP must agree to use adequate birth control throughout their participation and for
             3 months after RP1 alone and 5 months after nivolumab last study treatment

          -  Males with partners of child-bearing potential must agree to use adequate birth
             control throughout their participation and for 3 months for RP1 alone and 7 months
             after nivolumab last study treatment

        For Subjects in the Combination Treatment

          -  Baseline ECG that does not show abnormalities according to the protocol

          -  Baseline oxygen saturation levels that do not show abnormalities according to the
             protocol

          -  Have provided a former tumor pathology specimen or be willing to supply a new tumor
             sample from a biopsy

        For Subjects in Phase 2 only

          -  Have a predicted life expectancy of ≥ 3 months

          -  Evaluable or measurable disease, according to Response Evaluation Criteria in Solid
             Tumors (RECIST) v1.1 criteria,

          -  Subjects with melanoma: has Stage IIIb to IV (skin, eye or mucosal) for whom anti PD-1
             therapy is indicated or who have previously received an anti-PD-1 therapy, or have
             refused, become intolerant to or have no further therapy options available

          -  Subjects with MSI-H tumors: has diagnosis of MSI-H tumor (according to protocol
             definition) for whom anti PD-1 therapy is indicated, or have refused, become
             intolerant to or have no further therapy options available

          -  Subject with dMMR tumors: has diagnosis of dMMR tumor (according to protocol
             definition) for whom anti PD-1 therapy is indicated, or have refused, become
             intolerant to or have no further therapy options available

          -  Subject with NMSC: has diagnosis of locally advanced or metastatic NMSC that are not
             considered treatable by surgery including basal cell carcinoma, cutaneous squamous
             cell carcinoma, basosquamous carcinoma, Merkel cell carcinoma and other non-melanoma
             skin cancers (per protocol) for whom anti PD-1 therapy is indicated, or have refused,
             become intolerant to or have no further therapy options available

          -  Subjects with bladder cancer: diagnosis of locally advanced or metastatic bladder
             cancer for whom anti PD-1 therapy is indicated, or have refused, become intolerant to
             or have no further therapy options available

          -  Subjects with cutaneous melanoma, that have confirmed progressive disease after at
             least 12 weeks of anti-PD1 treatment

        Exclusion Criteria:

          -  Prior treatment with an oncolytic therapy

          -  History of viral infections according to the protocol

          -  Systemic infection requiring IV antibiotics within 14 days prior to dosing

          -  Prior complications with herpes infections

          -  Chronic use of anti-virals

          -  Systemic therapies for cancer within 4 weeks of first dose (some others may be
             accepted with shorter time periods)

          -  Conditions that require certain doses of steroids (some doses and types will be
             permitted)

          -  Known active brain metastases - previously treated brain metastases may be permitted

          -  Prior certain other diagnosis of cancer

          -  Is participating in another clinical study or has participated in the past 4 weeks
             prior to the first dose

        Combination Phase Subjects

          -  Certain autoimmune diseases, some types will be permitted

          -  Allergy or sensitivity to study drug components

          -  History of interstitial lung disease

          -  History of non-infectious pnuemonitis

          -  Other serious or uncontrolled medical disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Selda Samakoglu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Replimune Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gail Iodice</last_name>
    <phone>1(857) 701 2235</phone>
    <email>RPL-001-16@replimune.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama- The Kirklin Clinic</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35243</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsey Stephens, RN</last_name>
      <phone>205-978-4332</phone>
      <email>lmeggs@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Conry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jenesse Moffett</last_name>
      <phone>480-256-5422</phone>
      <email>Jenesse.moffett@bannerhealth.com</email>
    </contact>
    <investigator>
      <last_name>Jiaxin Niu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California- San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Chow</last_name>
      <email>Melissa.chow@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Katy Tsai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale School of Medicine- Smilow Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthew Piscatelli</last_name>
      <email>Matthew.piscatelli@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Shelby DeCarlo</last_name>
      <email>shelby.decarlo@yale.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Daniel Petrylak, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center- University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reisy Guedes</last_name>
      <phone>305-243-8807</phone>
      <email>rxg957@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Jamie Merchan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa-Cancer Center Research</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariel McKay</last_name>
      <email>mariel-mckay@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Mohammed Milhem, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>James Graham Brown Cancer Center- University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy Baum</last_name>
      <phone>502-562-2280</phone>
      <email>mary.baum@louisville.edu</email>
    </contact>
    <investigator>
      <last_name>Jason Chesney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Summit Medical Group</name>
      <address>
        <city>Florham Park</city>
        <state>New Jersey</state>
        <zip>07932</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Mackenzie</last_name>
      <email>mmackenzie@smgnj.com</email>
    </contact>
    <contact_backup>
      <last_name>Amy Lumpkin</last_name>
      <email>alumpkin@smgnj.com</email>
    </contact_backup>
    <investigator>
      <last_name>William DeRosa, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University Clinical Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mackenzie Tsang-Lee, RN</last_name>
      <phone>212-731-5431</phone>
      <email>mailto:Mackenzie.Tsang-lee@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Anna Pavlick, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Mitchell</last_name>
      <email>laura.mitchell@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Rachael Turner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Pomeroy</last_name>
      <phone>503-215-2714</phone>
      <email>Melissa.Pomeroy@providence.org</email>
    </contact>
    <investigator>
      <last_name>Brendan Curti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Cancer Center</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alisa Harber</last_name>
      <phone>901-683-0055</phone>
      <phone_ext>61304</phone_ext>
      <email>aharber@westclinic.com</email>
    </contact>
    <investigator>
      <last_name>Ari Vanderwalde, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Research Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raquel Bunge</last_name>
      <email>rrbung2@houstonmethodist.org</email>
    </contact>
    <contact_backup>
      <last_name>Sharell Cornett-Risher</last_name>
      <email>scornett-risher@houstonmethodist.org</email>
    </contact_backup>
    <investigator>
      <last_name>Maen Abdelrahim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eccles Outpatient Care Center- Oncology Clinical Trials</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tricia Fullmer</last_name>
      <email>tricia.fullmer@imail.org</email>
    </contact>
    <investigator>
      <last_name>Tawnya Bowles, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Intermountain Cancer Center- Saint George Cancer Center</name>
      <address>
        <city>Saint George</city>
        <state>Utah</state>
        <zip>84790</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angi Cox</last_name>
      <email>angi.cox@imail.org</email>
    </contact>
    <investigator>
      <last_name>Terence Rhodes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance- University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannah Lee</last_name>
      <email>hpiek@seattlecca.org</email>
    </contact>
    <contact_backup>
      <last_name>Grace Neal</last_name>
      <email>nealg@seattlecca.org</email>
    </contact_backup>
    <investigator>
      <last_name>Kit Wong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin-Carbone Cancer Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Forsyth</last_name>
      <phone>608-263-6222</phone>
      <email>ajforsyth@medicine.wisc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Chris Feierabend</last_name>
      <email>caf@medicine.wisc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Hamid Emamekhoo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin- Cancer Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Fleischman, RN</last_name>
      <phone>414-805-3645</phone>
      <email>jfleischman@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Benjamin George, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Leeds- Teaching Hospital</name>
      <address>
        <city>Leeds</city>
        <state>England</state>
        <zip>LS97TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>leedsth-tr.oncologytrials@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Adel Samson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Trust</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mark R Middleton, MD,PhD,FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Center</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Patricia Roxburgh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Clatterbridge Cancer Centre NHS Foundation Trust</name>
      <address>
        <city>Bebington</city>
        <state>Wirral</state>
        <zip>CH634JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+44 1515565212</phone>
      <email>joseph.sacco@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Joseph Sacco, MRCP, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Marsden Hospital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+44 2073528171</phone>
      <phone_ext>1149</phone_ext>
      <email>H&amp;NResearchnursefulham@rmh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Kevin Harrington, BSc FRCP PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 5, 2018</study_first_submitted>
  <study_first_submitted_qc>December 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2018</study_first_posted>
  <last_update_submitted>May 21, 2020</last_update_submitted>
  <last_update_submitted_qc>May 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
    <mesh_term>Microsatellite Instability</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

